Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ITU-512 by Novartis for Sickle Cell Disease: Likelihood of Approval
ITU-512 is under clinical development by Novartis and currently in Phase II for Sickle Cell Disease. According to GlobalData, Phase...